Citations

Mayo Clinic

Showing 10 of 108551 citations.

Prognostic Immunohistochemistry for Ki-67 and OTP on Small Biopsies of Pulmonary Carcinoid Tumors
Jenkins, Sarah M. , Roden, Anja C. , Yi, Euhee S., Bois, Melanie C. , Maleszewski, Joseph J. , Aubry, Marie Christine, Naso, Julia , Yi, Eunhee S. , Lo, Ying‐Chun , Boland, Jennifer M.

American Journal of Surgical Pathology | April 8, 2024 | Volume: 48 | Issue: 6 | Pages: 742-750

10.1097/pas.0000000000002227 | PMID 38584496 Get It

Prognostic stratification of pulmonary carcinoids into “typical” and “atypical” categories requires examination of large tissue volume. However, there is a need for tools that provide similar prognostic information on small biopsy samples. Ki-67 and OTP immunohistochemistry have shown promising prognostic value in studies of resected pulmonary carcinoids, but prognostic value when using biopsy/cytology specimens is unclear. Ki-67 immunohistochemistry was performed on small biopsy/cytology specimens from pulmonary carcinoid tumors (n=139), and labeling index was scored via automated image analysis of at least 500 cells. OTP immunohistochemistry was performed on 70 cases with sufficient tissue and scored as positive or negative (<20% tumor nuclei staining). Higher Ki-67 index was associated with worse disease-specific progression-free survival (ds-PFS), with 3% and 4% thresholds having similarly strong associations with ds-PFS ( P <0.001, hazard ratio ≥11). Three-year ds-PFS was 98% for patients with Ki-67 <3% and 89% for patients with Ki-67≥3% ( P =0.0006). The optimal Ki-67 threshold for prediction of typical versus atypical carcinoid histology on subsequent resection was 3.21 (AUC 0.68). Negative OTP staining approached significance with atypical carcinoid histology ( P =0.06) but not with ds-PFS ( P =0.24, hazard ratio=3.45), although sample size was limited. We propose that Ki-67 immunohistochemistry may contribute to risk stratification for carcinoid tumor patients based on small biopsy samples. Identification of a 3% hot-spot Ki-67 threshold as optimal for prediction of ds-PFS is notable as a 3% Ki-67 threshold is currently used for gastrointestinal neuroendocrine tumor stratification, allowing consideration of a unified classification system across organ systems.
Perspectives on AI-based recommendations for mask-wearing and COVID-19 vaccination for transplant recipients in the post-COVID-19 era
Valencia, Oscar A. Garcia , Miao, Jing , Craici, Iasmina , Cheungpasitporn, Wisit , Garcia Valencia, Oscar A, Craici, Iasmina M, Cheungpasitporn, Wisit , Garcia-Valencia, Oscar , Miao, Jing , Thongprayoon, Charat , Bruminhent, Jackrapong

Renal Failure | April 8, 2024 | Volume: 46 | Issue: 1 | Pages: No page available

10.1080/0886022x.2024.2337291 | PMID 38584142 Get It

Allelic heterogeneity of TTNtv dilated cardiomyopathy can be modeled in adult zebrafish
Zhu, Ping , Li, Jiarong , Yan, Feixiang , Xu, Xiaolei , Islam, Shahidul, Lin, Xueying , Islam, Shahidul

JCI Insight | April 7, 2024 | Volume: 9 | Issue: 7 | Pages: No page available

10.1172/jci.insight.175501 | PMID 38412038 Get It

Allelic heterogeneity (AH) has been noted in truncational TTN –associated ( TTNtv -associated) dilated cardiomyopathy (DCM); i.e., mutations affecting A-band–encoding exons are pathogenic, but those affecting Z-disc–encoding exons are likely benign. The lack of an in vivo animal model that recapitulates AH hinders the deciphering of the underlying mechanism. Here, we explored zebrafish as a candidate vertebrate model by phenotyping a collection of zebrafish ttntv alleles. We noted that cardiac function and sarcomere structure were more severely disrupted in ttntv-A than in ttntv-Z homozygous embryos. Consistently, cardiomyopathy-like phenotypes were present in ttntv-A but not ttntv-Z adult heterozygous mutants. The phenotypes observed in ttntv-A alleles were recapitulated in null mutants with the full titin -encoding sequences removed. Defective autophagic flux, largely due to impaired autophagosome-lysosome fusion, was also noted only in ttntv-A but not in ttntv-Z models. Moreover, we found that genetic manipulation of ulk1a restored autophagy flux and rescued cardiac dysfunction in ttntv-A animals. Together, our findings presented adult zebrafish as an in vivo animal model for studying AH in TTNtv DCM, demonstrated TTN loss of function is sufficient to trigger ttntv DCM in zebrafish, and uncovered ulk1a as a potential therapeutic target gene for TTNtv DCM.
A complement C4–derived glycopeptide is a biomarker for PMM2-CDG
Garapati, Kishore , Budhraja, Rohit , Saraswat, Mayank , Joshi, Neha , Sachdeva, Gunveen S. , Jain, Anu, Ligezka, Anna N. , Radenkovic, Silvia , Ramarajan, Madan Gopal , Udainiya, Savita, Raymond, Kimiyo , Lam, Christina , Edmondson, Andrew C. , Sarafoglou, Kyriakie , Larson, Nicholas B. , Kim, Jinyong, Edmondson, Andrew C , Larson, Nicholas B , Joshi, Neha S , Ramarajan, Madan G , Garapati, Kishore , Kim, Jin Yong , He, Miao , Larson, Austin , Freeze, Hudson H. , Schultz, Matthew , Kozicz, Tamás , Morava, Éva , Pandey, Akhilesh

JCI Insight | April 7, 2024 | Volume: 9 | Issue: 7 | Pages: No page available

10.1172/jci.insight.172509 | PMID 38587076 Get It

BACKGROUND Diagnosis of PMM2-CDG, the most common congenital disorder of glycosylation (CDG), relies on measuring carbohydrate-deficient transferrin (CDT) and genetic testing. CDT tests have false negatives and may normalize with age. Site-specific changes in protein N-glycosylation have not been reported in sera in PMM2-CDG. METHODS Using multistep mass spectrometry–based N-glycoproteomics, we analyzed sera from 72 individuals to discover and validate glycopeptide alterations. We performed comprehensive tandem mass tag–based discovery experiments in well-characterized patients and controls. Next, we developed a method for rapid profiling of additional samples. Finally, targeted mass spectrometry was used for validation in an independent set of samples in a blinded fashion. RESULTS Of the 3,342 N-glycopeptides identified, patients exhibited decrease in complex-type N-glycans and increase in truncated, mannose-rich, and hybrid species. We identified a glycopeptide from complement C4 carrying the glycan Man 5 GlcNAc 2 , which was not detected in controls, in 5 patients with normal CDT results, including 1 after liver transplant and 2 with a known genetic variant associated with mild disease, indicating greater sensitivity than CDT. It was detected by targeted analysis in 2 individuals with variants of uncertain significance in PMM2 . CONCLUSION Complement C4–derived Man 5 GlcNAc 2 glycopeptide could be a biomarker for accurate diagnosis and therapeutic monitoring of patients with PMM2-CDG and other CDGs. FUNDING U54NS115198 (Frontiers in Congenital Disorders of Glycosylation: NINDS; NCATS; Eunice Kennedy Shriver NICHD; Rare Disorders Consortium Disease Network); K08NS118119 (NINDS); Minnesota Partnership for Biotechnology and Medical Genomics; Rocket Fund; R01DK099551 (NIDDK); Mayo Clinic DERIVE Office; Mayo Clinic Center for Biomedical Discovery; IA/CRC/20/1/600002 (Center for Rare Disease Diagnosis, Research and Training; DBT/Wellcome Trust India Alliance)
Successful prediction of left bundle branch block‐induced cardiomyopathy and treatment effect by artificial intelligence‐enabled electrocardiogram
Carpenter, Caitlin, Friedman, Paul A. , Dhawan, Rahul, Friedman, Paul A , Dhawan, Rahul , Omer, Mohamed , Liu, Xiaoke

Pacing and Clinical Electrophysiology | April 7, 2024 | Volume: 47 | Issue: 6 | Pages: 776-779

10.1111/pace.14980 | PMID 38583090 Get It

AbstractBackgroundLeft bundle branch block (LBBB) induced cardiomyopathy is an increasingly recognized disease entity. However, no clinical testing has been shown to be able to predict such an occurrence.Case reportA 70‐year‐old male with a prior history of LBBB with preserved ejection fraction (EF) and no other known cardiovascular conditions presented with presyncope, high‐grade AV block, and heart failure with reduced EF (36%). His coronary angiogram was negative for any obstructive disease. No other known etiologies for cardiomyopathy were identified. Artificial intelligence‐enabled ECGs performed 6 years prior to clinical presentation consistently predicted a high probability (up to 91%) of low EF. The patient successfully underwent left bundle branch area (LBBA) pacing with correction of the underlying LBBB. Subsequent AI ECGs showed a large drop in the probability of low EF immediately after LBBA pacing to 47% and then to 3% 2 months post procedure. His heart failure symptoms markedly improved and EF normalized to 54% at the same time.ConclusionsArtificial intelligence‐enabled ECGS may help identify patients who are at risk of developing LBBB‐induced cardiomyopathy and predict the response to LBBA pacing.
Gammopathic dermopathy: characterization of cutaneous MGUS
Gordon, Emily R. , Chen, Caroline, Trager, Megan H. , Adeuyan, Oluwaseyi , Fahmy, Lauren M. , Schreidah, Celine M. , Wetter, David A. , Lapolla, Brigit A. , Geskin, Larisa J.

Leukemia & Lymphoma | April 6, 2024 | Volume: 65 | Issue: 7 | Pages: 989-996

10.1080/10428194.2024.2336046 | PMID 38581379 Get It

The role of occipital condyle and atlas anomalies on occipital cervical fusion outcomes in Chiari malformation type I with syringomyelia: a study from the Park-Reeves Syringomyelia Research Consortium
Koueik, Joyce , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Bauer, David F. , Bethel-Anderson, Tammy, Bierbrauer, Karin S. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Kaufman, Bruce A., Keating, Robert F., Krieger, Mark D., Leonard, Jeffrey R. , Maher, Cormac O. , Mangano, Francesco T. , Martin, Jonathan E. , McComb, J. Gordon , McEvoy, Sean D., Meehan, Thanda, Muhlbauer, Michael S., O’Neill, Brent R., Olavarria, Greg, Ragheb, John , Shannon, Chevis N. , Stone, Scellig , Strahle, Jennifer M. , Tamber, Mandeep S. , Torner, James C., Tuite, Gerald F. , Tyler‐Kabara, Elizabeth C. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Limbrick, David D. , Torner, James C. , Yahanda, Alexander T. , Daniels, David J. , Dlouhy, Brian J , Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J., Jackson, Eric M. , Jallo, George I. , Johnston, James M. , Khan, Nickalus R. , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Park, Tae Sung , Limbrick, David D. , Ahmed, Raheel

Journal of Neurosurgery: Pediatrics | April 6, 2024 | Volume: 34 | Issue: 1 | Pages: 66-74

10.3171/2024.1.peds23229 | PMID 38579359 Get It

OBJECTIVE Congenital anomalies of the atlanto-occipital articulation may be present in patients with Chiari malformation type I (CM-I). However, it is unclear how these anomalies affect the biomechanical stability of the craniovertebral junction (CVJ) and whether they are associated with an increased incidence of occipitocervical fusion (OCF) following posterior fossa decompression (PFD). The objective of this study was to determine the prevalence of condylar hypoplasia and atlas anomalies in children with CM-I and syringomyelia. The authors also investigated the predictive contribution of these anomalies to the occurrence of OCF following PFD (PFD+OCF). METHODS The authors analyzed the prevalence of condylar hypoplasia and atlas arch anomalies for patients in the Park-Reeves Syringomyelia Research Consortium database who underwent PFD+OCF. Condylar hypoplasia was defined by an atlanto-occipital joint axis angle (AOJAA) ≥ 130°. Atlas assimilation and arch anomalies were identified on presurgical radiographic imaging. This PFD+OCF cohort was compared with a control cohort of patients who underwent PFD alone. The control group was matched to the PFD+OCF cohort according to age, sex, and duration of symptoms at a 2:1 ratio. RESULTS Clinical features and radiographic atlanto-occipital joint parameters were compared between 19 patients in the PFD+OCF cohort and 38 patients in the PFD-only cohort. Demographic data were not significantly different between cohorts (p > 0.05). The mean AOJAA was significantly higher in the PFD+OCF group than in the PFD group (144° ± 12° vs 127° ± 6°, p < 0.0001). In the PFD+OCF group, atlas assimilation and atlas arch anomalies were identified in 10 (53%) and 5 (26%) patients, respectively. These anomalies were absent (n = 0) in the PFD group (p < 0.001). Multivariate regression analysis identified the following 3 CVJ radiographic variables that were predictive of OCF occurrence after PFD: AOJAA ≥ 130° (p = 0.01), clivoaxial angle < 125° (p = 0.02), and occipital condyle–C2 sagittal vertical alignment (C–C2SVA) ≥ 5 mm (p = 0.01). A predictive model based on these 3 factors accurately predicted OCF following PFD (C-statistic 0.95). CONCLUSIONS The authors’ results indicate that the occipital condyle–atlas joint complex might affect the biomechanical integrity of the CVJ in children with CM-I and syringomyelia. They describe the role of the AOJAA metric as an independent predictive factor for occurrence of OCF following PFD. Preoperative identification of these skeletal abnormalities may be used to guide surgical planning and treatment of patients with complex CM-I and coexistent osseous pathology.
Extraocular muscle electromyographic recordings for intraoperative monitoring of cranial nerves III, IV, and VI: a single-center experience with intraorbital electrodes
Oishi, Tatsuya , Link, Michael J. , Celda, María Peris, Hoffman, E. Matthew , Gompel, Jamie J. Van , Daniels, David J., Morris, Jonathan M.

Journal of Neurosurgery | April 6, 2024 | Volume: 141 | Issue: 3 | Pages: 730-741

10.3171/2024.1.jns231867 | PMID 38579353 Get It

OBJECTIVE The objective of this study was to describe the quantitative features of intraoperative electromyographic recordings obtained from cranial nerve III, IV, and VI neuromonitoring using 25-mm intraorbital electrodes, in the larger context of demonstrating the practicality of this technique during neurosurgical cases. METHODS A 25-mm-long shaft-insulated intraorbital needle electrode is routinely used at the authors’ institution for extraocular muscle (EOM) electromyographic monitoring of the inferior rectus, superior oblique, and/or lateral rectus muscles when their function is at risk. Cases monitored between January 1, 2021, and December 31, 2022, were reviewed for patient demographics, tumor location and pathology, EOMs monitored, pre- and postoperative examination, and complications from electrode placement. Compound muscle action potentials on triggered electromyography, as well as neurotonic discharges on free-run electromyography, were described quantitatively. RESULTS There were 141 cases in 139 patients reviewed during the 24-month time span, with 278 EOMs monitored (inferior rectus/superior oblique/lateral rectus muscles 68/68/142). Triggered electromyography yielded biphasic or triphasic compound muscle action potentials from EOMs with a mean onset latency of 1.51 msec (range 0.94–3.22 msec), mean maximal peak-to-trough amplitude of 1073.93 μV (range 76.75–7796.29 μV), and high specificity for the channel in nearly all cases. Neurotonic discharges were recorded in 30 of the 278 EOMs (with all 3 muscles represented) and associated with a greater incidence of new or worsened ophthalmoparesis (OR 4.62, 95% CI 1.3–16.4). There were 2 cases of small periorbital ecchymosis attributed to needle placement; additionally, 1 case of needle-related intraorbital hematoma occurred after the review period. CONCLUSIONS The 25-mm shaft-insulated intraorbital electrode facilitates robust and consistent electromyographic recordings of EOMs that are advantageous over existing techniques. Combined with the relative ease of needle placement and low rate of complications, the technique is practical for neuromonitoring during craniotomies.
Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro
Dias, Moisés , Pinto, Marcus Vinícius , Rosa, Renata Gervais Santa , Accioli, Paula , Amorim, Gabriela , Guedes, Mariana Cardoso , Gomes, Carlos Perez , Pedrosa, Roberto Coury , Waddington‐Cruz, Márcia , Pinto, Luiz Felipe , Pinto, Marcus V , Gervais, Renata , Accioli, Paula , Amorim, Gabriela , Guedes, Mariana , Gomes, Carlos Perez , Pedrosa, Roberto Coury , Waddington-Cruz, Márcia , Dias, Moises , Pinto, Luiz Felipe

Arquivos de Neuro-Psiquiatria | April 5, 2024 | Volume: 82 | Issue: 04 | Pages: 001-007

10.1055/s-0044-1781463 | PMID 38579737 Get It

Abstract Background Hereditary transthyretin amyloidosis (ATTRv) is an inherited, progressive, and fatal disease still largely underdiagnosed. Mutations in the transthyretin (TTR) gene cause the TTR protein to destabilize, misfold, aggregate, and deposit in body tissues, which makes ATTRv a disease with heterogeneous clinical phenotype. Objective To describe the long-term efficacy and safety of inotersen therapy in patients with ATTRv peripheral neuropathy (ATTRv-PN). Methods Patients who completed the NEURO-TTR pivotal study and the NEURO-TTR OLE open-label extension study migrated to the present study and were followed-up for at least 18 more months to an average of 67 months and up to 76 months since day 1 of the inotersen therapy (D1–first dose of inotersen). Disease progression was evaluated by standard measures. Results Ten ATTRv-PN patients with Val30Met mutation were included. The mean disease duration on D1 was of 3 years, and the mean age of the patients was of 46.8 years. During an additional 18-month follow up, neurological function, based on the Neuropathy Impairment Score and the Polyneuropathy Disability Score, functionality aspects (Karnofsky Performance Status), and nutritional and cardiac aspects were maintained. No new safety signs have been noted. Conclusion The treatment with inotersen was effective and well tolerated for the average of 67 months and up to 76 months. Our results are consistent with those of larger phase-III trials.
Efficacy and safety of tranexamic acid in the management of chronic subdural hematoma: a systematic review and meta-analysis
Salim, Hamza , Adeeb, Nimer , Spellicy, Samantha , Abdelgadir, Jihad , Guthikonda, Bharat , Azar, Jehad , Salim, Hamza , Musmar, Basel , Orscelik, Atakan , Cuellar, Hugo , Jabbour, Pascal , Hasan, David

Journal of Neurosurgery | April 5, 2024 | Volume: 141 | Issue: 4 | Pages: 945-954

10.3171/2024.1.jns232463 | PMID 38579356 Get It

OBJECTIVE Chronic subdural hematoma (CSDH) is a prevalent neurosurgical condition, particularly among the elderly. Various treatment options exist, but recurrence rates remain high. This systematic review and meta-analysis aims to assess the efficacy and safety of tranexamic acid (TXA) in the management of CSDH. METHODS The authors conducted a comprehensive literature search adhering to the 2020 PRISMA guidelines, involving three primary databases (Scopus, PubMed, and Web of Science) that were searched for articles compiled from inception until October 20, 2023. The primary outcome was recurrence of CSDH, and secondary outcomes included complications and SDH volume following TXA treatment. The mean difference and odds ratios with 95% confidence intervals were calculated using the random-effects model. RESULTS A total of 5 studies, involving 643 patients in the TXA group and 736 patients in the non-TXA group, met the inclusion criteria. The meta-analysis revealed that TXA use led to a significantly lower CSDH recurrence (OR 0.35, 95% CI 0.23–0.53; p < 0.01) without increasing complications (OR 1.84, 95% CI 0.43–7.95; p = 0.42). Additionally, TXA users had a significantly lower CSDH volume compared to the non-TXA group at 3-month follow-up (mean difference −4.56, 95% CI −8.76 to −0.36; p = 0.03). CONCLUSIONS The findings suggest that TXA might be a promising agent for reducing the risk of CSDH recurrence without elevating the risk of complications. However, these results should be interpreted cautiously due to the limited number of studies included and the methodological heterogeneity. Further large-scale randomized controlled trials are needed to confirm these findings.